All News

lupus.jpg

Older Lupus Patients Need Follow-Up After Hospital Discharge

MedPage Today

Medicare beneficiaries 65 and older with lupus faced dramatically higher mortality when they received no follow-up care during the month after a hospital stay, researchers found.

Read Article
Cutaneous.lupus.SLE.Face.dermnetnz

Deucravacitinib - Effective in Systemic Lupus Erythematosus

Jack Cush, MD

A Phase II, multicenter study has demonstrated the efficacy and safety of deucravacitinib, an oral, selective, allosteric inhibitor of TYK2, in  adults with active systemic lupus erythematosus (SLE).

Read Article
genes.map_.jpg

Pathogenic Impact of microRNA Cotargeting in Lupus

EurekAlert!

A group of researchers from the Graduate School of Medicine at Nagoya University in Japan have discovered the impact of microRNA (miRNA) on inflammation in lupus in mice.

Read Article
RheumNow Podcast square

Simon Says “Don’t Do This” (1.27.2022)

Jack Cush, MD

Dr. Jack Cush reviews this week’s journal articles, focuses on studies that should not have been done and responds to viewer questions in Ask Cush Anything.

Read Article
pregnant.baby_.hands_.jpg

Variable Pregnancy Outcomes with Belimumab in SLE

Jack Cush, MD

An analysis of the belimumab clinical trials, the Belimumab Pregnancy Registry (BPR), and postmarketing/spontaneous reports looked at outcomes in pregnant systemic lupus erythematosus (SLE) exposed to belimumab reported there are few pregnancies and confounding disease and comorbidity factors to

Read Article
eye%20exa.jpg (keep)

Hydroxychloroquine Dose and Risk for Incident Retinopathy

Jack Cush, MD

A cohort study in Annals of Internal Medicine shows that higher hydroxychloroquine doses was associated with progressively greater risk for incident retinopathy.

Read Article
Deucravacitinib - Effective in Systemic Lupus Erythematosus A Phase II, multicenter study has demonstrated the efficacy and safety of deucravacitinib, an oral, selective, allosteric inhibitor of TYK2, in adults with active SLE. https://t.co/0g2VM6TJt6 https://t.co/f6wylPc5ep

Links:

Dr. John Cush RheumNow ( View Tweet)
Retrospective cohort study of Taiwan Health Insurance Database looked at risk of #SLE in pts w/ Hashimoto’s thyroiditis (HT). Compared 15K HTvs 31K controls. SLE was incr in HT pts (IRR 3.58; p < 0.01). Several sensitivity analyses aHR 4.35 to 5.11 https://t.co/QaWEN4Chw9 https://t.co/bD8zrCJEXY

Links:

Dr. John Cush RheumNow ( View Tweet)
NLRP12 is a negative regulator of innate immune activation and type I interferon production. SLE PBMCs have low levels NLRP12 (inverse correl w/ IFNa & Hi Dz activity. NLRP12 knockouts or deficiency Incr autoAbs, inflammation & renal damage https://t.co/VICAqKmK9r https://t.co/MxqcNzh6BQ

Links:

Dr. John Cush RheumNow ( View Tweet)
Meta-analysis (21 studies, 3948 pregnant pts) HCQ may reduce risk of preeclampsia (OR 0.45) & premature delivery (OR 0.84) in pregnant autoimmune pts. HCQ may also reduce risk of gestational HTN (OR 0.42) & pre-term birth (OR 0.63) in pregnant SLE pts https://t.co/riQDRN9r1A https://t.co/uR8Nem4Ndx

Links:

Dr. John Cush RheumNow ( View Tweet)
NLRP12 is a negative regulator of innate immune activation and type I interferon production. SLE PBMCs have low levels NLRP12 (inverse correl w/ IFNa & Hi Dz activity. NLRP12 knockouts or deficiency Incr autoAbs, inflammation & renal damage https://t.co/PjTQNHhduB https://t.co/m0erNXMkUC

Links:

Dr. John Cush RheumNow ( View Tweet)
New Guideline: Vaccinations OK With Few Tweaks for Rheum Patients Nearly all available vaccines can be given to people with rheumatologic diseases, according to a new, detailed guideline from the ACR. https://t.co/514mIylgzj https://t.co/9Zq9pGcujV

Links:

Dr. John Cush RheumNow ( View Tweet)
FDA has approved the 1st BTK (Bruton’s tyrosine kinase) inhibitor (Jaypirca™ or pirtobrutinib) for adults with refractory mantle cell lymphoma. BTK inhibitors are also being developed for use in MS, RA, SLE, pemphigus & more https://t.co/599tK21H1Z https://t.co/KSqMMDWmfd

Links:

Dr. John Cush RheumNow ( View Tweet)
Feb 3rd, today is #NationalWomenPhysiciansDay. The date honors Dr. Elizabeth Blackwell, 1st woman to receive an MD United States (1849). RheumNow will devote the whole month of April 2023 to our Campaign on Women in Rheumatology - stay tuned! https://t.co/l1M56L8h9N https://t.co/eQpetW02CE

Links:

Dr. John Cush RheumNow ( View Tweet)
Pathogenic Impact of microRNA Cotargeting in Lupus A group of researchers from the Graduate School of Medicine at Nagoya University in Japan have discovered the impact of microRNA (miRNA) on inflammation in lupus in mice. https://t.co/j0TRgIaam6 https://t.co/HNJbsTfT7c

Links:

Dr. John Cush RheumNow ( View Tweet)
Rheumatic Disease - IBD Overlap Nearly one in 10 patients with IBD also have rheumatologic disorders, meaning that specialists have to talk to each other to develop a treatment plan that works for both conditions, a researcher suggested. https://t.co/s3u9q8Sw9Y https://t.co/RjFyEcm6FA

Links:

Dr. John Cush RheumNow ( View Tweet)
Variable Pregnancy Outcomes with Belimumab in SLE An analysis looked at outcomes in pregnant SLE exposed to belimumab reported there are few pregnancies and confounding disease and comorbidity factors to provide clear guidance for such patients. https://t.co/nBzoyL4cHW https://t.co/UYIAsfRtB8

Links:

Dr. John Cush RheumNow ( View Tweet)
702 #SLE pts (age 29 yrs) from India, measured plasma 25-hydroxyvitamin-D(25(OH)D) - median levels were 22.83 (13.8–31.8) ng/ml. Low Vit D(< 20) seen in 41.5%; correlated w/ age/geography, & weak neg correlation w/ weak negative correlation w/ SLEDAI2K https://t.co/EUPqJGKAhI https://t.co/MEIL5yd64n

Links:

Dr. John Cush RheumNow ( View Tweet)
Have a Rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/RaFKTqhQjN https://t.co/hH0NcpOoyx

Links:

Dr. John Cush RheumNow ( View Tweet)
Inpatient health care utilization studied in 341 #SLE pts vs 341 non-SLE. SLE had more hospitalizations (30 vs 10/100PY) and more ED visit (HR 2.71) and Hospital readmission rates (32% vs. 21%, p = 0.017) https://t.co/vsW7Ol9b4O https://t.co/hpmcFuF8Pm

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×